Plasma amino acids indicate glioblastoma with ATRX loss
| Autor: | Malgorzata Chmielewska-Kassassir, Karolina Janczar, Michał Bieńkowski, Dariusz J. Jaskólski, Dorota Szczesna, Lucyna A. Wozniak, Karol Wiśniewski, Wielisław Papierz, Ernest J. Bobeff |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty X-linked Nuclear Protein Arginine Clinical Biochemistry Phenylalanine Biochemistry 03 medical and health sciences Internal medicine Glioma Biomarkers Tumor Medicine Humans Metabolomics Amino Acids ATRX Aged chemistry.chemical_classification 030102 biochemistry & molecular biology business.industry Brain Neoplasms Organic Chemistry Middle Aged medicine.disease Prognosis Amino acid Glutamine 030104 developmental biology Endocrinology chemistry Biomarker (medicine) Female Leucine business Glioblastoma |
| Zdroj: | Amino acids. 53(1) |
| ISSN: | 1438-2199 |
| Popis: | Glioblastoma (GB) is the most common primary brain tumour in adults. The lack of molecular biomarker, non-specific symptoms and fast growth rate often result in a significant delay in diagnosis. Despite multimodal treatment, the prognosis remains poor. Here, we verified the hypothesis that amino acids (AA) regulating the critical metabolic pathways necessary for maintenance, growth, reproduction, and immunity of an organism, may constitute a favourable target in GB biomarker research. We measured the plasma amino acids levels in 18 GB patients and 15 controls and performed the quantitative and qualitative metabolomic analysis of free AA applying high-performance liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). We present both the raw data and the results of our statistical analysis. The majority of AA were lowered in the study group in comparison to the control group. Five of these (arginine, glutamic acid, glutamine, glycine, and histidine) differed significantly (all p 0.9). Plasma levels of leucine and phenylalanine decreased in the case of GB with lost alpha-thalassemia/mental retardation X-linked (ATRX) expression on immunohistochemistry (p = 0.003 and 0.045, respectively). We demonstrated for the first time that certain plasma-free AA levels of GB patients were significantly different from those in healthy volunteers. Target profiling of plasma-free AA, identified utilizing LC-QTOF-MS, may present prognostic value by indicating GB patients with lost ATRX expression. The on-going quest for glioma biomarkers still aims to determine the detailed metabolic profile and evaluate its impact on therapy and prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink